" class="no-js "lang="en-US"> Stephen Towe - Medtech Alert
Thursday, July 31, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Stephen Towe

Stephen Towe

About Stephen Towe

CEO with over 8 years experience in an innovative and heavily regulated medical device industry. Combining solid technical understanding with an ability to connect with others forming the bridge between the technical and commercial world.

Stephen Towe is the Chief Executive Officer and Co-Founder of Leo Cancer Care. Having successfully driven the design of the Leo Cancer Care technology in Australia Stephen took over the role of CEO in 2018. Since then, Stephen has led the expansion of Leo across both the US and Europe. He has a successful track record of delivering the most innovative products in radiotherapy, having led development teams in the completion and release of the Elekta Unity MRI guided radiotherapy system. Stephen has built a career innovating and commercialising radiotherapy products in the United States, Australia and across Europe and thrives on challenging the norm and improving the quality of care.

Related Story

Diseases

 RaySearch and Leo Cancer Care Join Forces to Enable Upright Radiotherapy | Pharmtech Focus

RaySearch and Leo Cancer Care Join Forces to Enable Upright Radiotherapy

September 5 2022

A key milestone and partnership for the clinical implementation of upright radiotherapy has been announced. […]